The latest Novotech snapshot of Australian #clinicaltrial activity has been released. It indicates there’s upwards of an 80% return to business across some of our highest performing sites. Other key items to note are a broadly accepted use of #eSignature, a reduced impact on #IMP dispensing,and improved #HREC and #RGO timelines.
Does this reflect your experience locally? Please comment below on your existing challenges as we will use these to provoke conversation with our sector experts in our upcoming webinar : “Disruption, adaptation and adoption: What does the new face of Clinical Trials look like?” 20th August.
Enrol here: https://lnkd.in/gJdQfrM